Mitochondria-targeted peptide that stabilises cardiolipin in the inner membrane.
Typical dose range: 1–5 mg
Frequency: Daily
Route: Subcutaneous
Half-life: ~2.5 hours
Evidence level: Phase 3 (Barth syndrome)
Promising clinical data for mitochondrial diseases. Longevity / general-wellness use is extrapolation — interesting but unproven.